HealthPro BioVentures

Healthcare & Life Sciences Investment Banking

HealthPro BioVentures LLC provides strategic advisory and investment banking services to emerging companies in the healthcare and life sciences sectors. Today’s challenging healthcare market is our sole focus. Our highly experienced staff is comprised of financial professionals from within both the healthcare investment banking and life sciences communities. HealthPro is prepared to play a vital role in helping you secure the financial support and strategic partners that you need to reach your corporate objectives and to maximize your value. 

HealthPro BioVentures Expands Its Suite of Services for Life Sciences Companies Seeking Financial Solutions with Appointment of Dr. James Kuo, Managing Director

January 31, 2014  /  Martin Kratchman

New York City-based Investment Bank boutique HealthPro BioVentures announced today the appointment of James Kuo, M.D., M.B.A., as managing director of its newly opened San Diego, CA office. Dr. Kuo’s joining HealthPro expands the organization’s capabilities to include strategic management support, in addition to HealthPro’s ongoing services of capital financings, mergers and acquisitions, and licensing and partnering.

Read More

Transgene Biotek Signs MOU with Canadian Armour Therapeutics Inc.

January 30, 2014  /  Martin Kratchman

Transgene Biotek Ltd, one of India’s earliest biotechnology companies, signalled its continued westward expansion with the signing of a Memorandum-of-Understanding with Armour Therapeutics Inc. of Toronto, Canada. Transgene and Armour are exploring a strategic relationship to co-develop Armour’s drug candidates for reproductive cancers. Armour’s lead anti-relaxin molecule, AT-001, is being developed to treat hormone refractory prostate cancer.

Read More

OncoVista Sells AdnaGen Subsidiary: Total Sale Price Could Reach $65 Million Over Three Years When Milestones Achieved

January 29, 2014  /  Martin Kratchman

OncoVista Innovative Therapies, Inc. (OTCBB:OVIT.ob - News), a high-growth global biopharmaceutical company commercializing diagnostic tests for metastatic tumors, as well as developing targeted, personal anticancer therapies by utilizing tumor-associated biomarkers, recently announced that the Company had divested its majority holding of subsidiary AdnaGen AG.

Read More

Abraxis BioScience, Inc. and ProMetic Life Sciences Inc. Enter Into License Agreements for up to US $295 Million for Four Biopharmaceuticals

January 28, 2014  /  Martin Kratchman

HealthPro BioVentures, LLC of New York is pleased to announce that HealthPro has acted as advisor to ProMetic Life Sciences. Abraxis and ProMetic have recently entered into license agreements for up to US $295 million for four biopharmaceuticals. In addition, Abraxis has made an initial US $7 million equity investment in ProMetic, with future additional optional equity investments of up to US $25 million.

Read More

MedeFile International Engages HealthPro BioVentures to Pursue Strategic Marketing Partnerships in Healthcare Industry

January 26, 2014  /  Martin Kratchman

MedeFile International, Inc. (OTCQB: MDFI) (PINKSHEETS: MDFI), a leader in Internet-enabled Personal Health Record (iPHR) management solutions, today announced that it has engaged HealthPro BioVentures, LLC with the sole objective of pursuing and structuring strategic co-marketing partnerships and healthcare IT collaborations with companies operating within the global healthcare arena.

Read More

Corinthian Partners and HealthPro BioVentures Announce Strategic Collaboration

January 25, 2014  /  Martin Kratchman

HealthPro BioVentures, LLC and Corinthian Partners, LLC are pleased to announce a strategic collaboration in which both companies will share their respective resources and capabilities. HealthPro BioVentures is a boutique investment bank that  focuses solely in the Healthcare and Life Sciences sector. Corinthian Partners is an investment bank/ asset management group with a specialty in renewable energy and resources.

Read More

Select Additional Transactions

January 24, 2014  /  Martin Kratchman

HealthPro acted as advisor to TorreyPines Therapeutics.  Cenomed and TorreyPines Therapeutics entered into a licensing agreement in which Cenomed licensed rights to Phenserine, Posiphen and Bisnorcymcerine for use in Counterterrorism and Chemical Defense. 
http://biz.yahoo.com/bw/081008/20081008005262.html?.v=1


As strategic advisor to Cytokine PharmaSciences, HealthPro BioVentures out-licensed a clinical phase novel formulation of Pilocarpine to Marillion Pharmaceuticals.  HealthPro BioVentures negotiated and provided support roles to both companies. 
As advisor to Biocon Limited (India), HealthPro BioVentures successfully negotiated the License Agreement of G-CSF (granulated colony stimulating factor) to Abraxis Biosciences for North America and the European Union. 
http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_19/ai_n27316506


As advisor to Biocon Limited (India), HealthPro BioVentures  successfully negotiated the Licensing Agreement of Abraxane from Abraxis BioScience for use in India, South Asia and other territiries to Biocon. 
http://www.fdanews.com/newsletter/article?articleId=96975&issueId=10562


HealthPro BioVentures completed a strategic transaction between Cenomed, Inc., an Irvine company and Abraxis Bioscience, a multibillion dollar integrated pharmaceutical company based in Los Angeles, to pursue development of CNS compounds. HealthPro BioVentures acted as advisor to Cenomed. Cenomed BioSciences business development will continue to be supported by HealthPro BioVentures.    
www.cenomedbiosciences.com


HealthPro BioVentures completed a strategic licensing transaction for Marillion Pharmaceutical’s first clinical stage asset, a D5 analog cancer therapeutic.

 

Go Back